Health and Fitness Health and Fitness
Thu, February 12, 2009
[ 12:05 PM ] - Market Wire
Ligand Announces Fourth Quarter and Full Year 2008 Consolidated Financial Results
[ 12:00 PM ] - Market Wire
Cerus to Release Fourth Quarter and Year End 2008 Financial Results on February 26, 2009
[ 11:15 AM ] - Market Wire
Biovail Announces Fourth-Quarter 2008 Earnings Release, Conference-Call Details
[ 10:51 AM ] - Market Wire
Clinical Data, Inc. To Present at the Roth 21st Annual OC Growth Stock Conference
[ 10:30 AM ] - Market Wire
I-Flow Will Present at the Roth Capital Partners .. nce Wednesday, February 18, 2009 at 4:00 p.m. PST
[ 09:12 AM ] - Market Wire
InSight Health Services Holdings Corp. to Host Second Quarter Fiscal 2009 Results Conference Call
[ 09:00 AM ] - Market Wire
American Shared Hospital Services to Develop Prot .. iation Therapy Facility in San Francisco Bay Area
[ 07:33 AM ] - Market Wire
Oral Laquinimod for Multiple Sclerosis Granted Fast Track Status by FDA
[ 06:23 AM ] - Market Wire
Samenvatting: Emergent BioSolutions maakt bekend .. traxvaccin) marktautorisatie in India heeft ontva
[ 06:09 AM ] - Market Wire
Trinity Biotech: Trinity Biotech Announces Appoin .. of James D. Merselis as a Non-Executive Director
[ 05:15 AM ] - Market Wire
AVI BioPharma, Inc.: AVI BioPharma, Inc. Appoints Chief Medical Officer
[ 05:00 AM ] - Market Wire
Shareholder Group Led by Adrenalina Announces Nom .. didates for Election to the Pacific Sunwear Board
[ 04:00 AM ] - Market Wire
Curis Announces Genentech?s Initiation of Pivotal .. rial of GDC-0449 in Advanced Basal Cell Carcinoma
[ 04:00 AM ] - Market Wire
Hythiam Announces Presentation at the Roth 21st Annual OC Growth Stock Conference
[ 04:00 AM ] - Market Wire
Alnylam and Collaborators Present Data from Multi .. and Clinical Programs at RNAi Keystone Symposium
[ 03:30 AM ] - Market Wire
ARIAD Reports Financial Guidance for 2009 and Fourth Quarter and Year-End 2008 Financial Results
[ 03:30 AM ] - Market Wire
La Jolla Pharmaceutical Company Announces Negativ .. Efficacy Analysis for Riquent Phase 3 ASPEN Trial
[ 03:15 AM ] - Market Wire
Syneron Medical Ltd.: Syneron Reports Fourth Quarter and Full Year 2008 Results
[ 03:00 AM ] - Market Wire
Obagi Medical Products to Present at Two Investor Conferences in February and March
[ 03:00 AM ] - Market Wire
Merck & Co., Inc. Acquires Biologic Manufacturing .. pmental Follow-on Biologics Portfolio from Insmed
[ 03:00 AM ] - Market Wire
Antigenics to Report Fourth Quarter and Year-End .. s on February 19, 2009; Conference Call to Follow
[ 03:00 AM ] - Market Wire
BioDelivery Sciences to Present at the ROTH Capit .. l Partners 21st Annual OC Growth Stock Conference
[ 02:00 AM ] - Market Wire
Spectranetics to Hold 2008 Fourth Quarter Financial Results Conference Call on February 19
[ 02:00 AM ] - Market Wire
Osiris Reports Positive Two-Year Data on Stem Cell Treatment for Acute Myocardial Infarction
[ 01:09 AM ] - Market Wire
Emergent BioSolutions anuncia que BioThrax (Vacin .. Antraz) recebe autorizao de comercializao na ndia
Wed, February 11, 2009
[ 11:20 PM ] - Market Wire
Emergent BioSolutions annonce que BioThrax (Anthr .. sorb© contre le charbon) a reu l'autorisation de
[ 09:00 PM ] - Market Wire
Emergent BioSolutions gibt bekannt, dass BioThrax .. cine Adsorbed) Marktautorisierung in Indien erhlt
[ 09:00 PM ] - Market Wire
Emergent BioSolutions Announces That BioThrax (An .. Adsorbed) Receives Market Authorization in India
[ 09:00 PM ] - Market Wire
Emergent BioSolutions anuncia que BioThrax (Vacun .. recibe la autorizacin de comercializacin en la In
[ 09:00 PM ] - Market Wire
Riassunto: Emergent BioSolutions annuncia che Bio .. ed) ha ricevuto l'autorizzazione per la commercia

Riassunto: Emergent BioSolutions annuncia che BioThrax (Anthrax Vaccine Adsorbed) ha ricevuto l'autorizzazione per la commercia


Published on 2009-02-11 22:42:19, Last Modified on 2009-02-11 22:42:42 - Market Wire
  Print publication without navigation


ROCKVILLE, Maryland--([ BUSINESS WIRE ])--Emergent BioSolutions Inc. (NYSE:EBS) ha annunciato oggi che la Drugs Controller General of India (DCGI) ha emesso un certificato di registrazione per BioThrax® (Anthrax Vaccine Adsorbed), che permette la commercializzazione e la vendita del vaccino in India per aiutare nella prevenzione dell'infezione da antrace. Emergent BioSolutions ha firmato un accordo di commercializzazione con Biological E. Limited per la commercializzazione di BioThrax in India.

Il testo originale del presente annuncio, redatto nella lingua di partenza, è la versione ufficiale che fa fede. Le traduzioni sono offerte unicamente per comodità del lettore e devono rinviare al testo in lingua originale, che è l'unico giuridicamente valido.

Contributing Sources